Download PDF
Semin Neurol 2015; 35(06): 675-682
DOI: 10.1055/s-0035-1564684
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neuro-Oncologic Emergencies

Brian J. Scott
1   Department of Neurology, Lahey Hospital and Medical Center, Burlington, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
23 November 2015 (online)

    Permissions and Reprints

Abstract

Cancer can have diverse and widespread effects on the nervous system. Knowledge of the most common characteristic mechanisms by which cancer impacts the nervous system enables prompt diagnosis and appropriate management. Here, a variety of neuro-oncologic emergencies are reviewed. Mass effect, status epilepticus, pituitary apoplexy, and metastatic epidural spinal cord compression are emergencies that arise from direct effects of central nervous system neoplasms. Limbic encephalitis may result in hospitalization and at times critical illness, and is usually caused by antibody-mediated reactions to neoplasms. Treatment-related neuro-oncologic emergencies from the effects of radiation and chemotherapy in severe cases may also result in medical emergencies.

Keywords

neoplastic emergencies - epidural spinal cord compression - neurologic complications of chemotherapy - limbic encephalitis - status epilepticus - pituitary apoplexy
 

  • References

  • 1 Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol 2007; 81 (1) 61-65
    PubMedGoogle Scholar
  • 2 Ostrom QT, Gittleman H, Liao P , et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 2014; 16 (Suppl. 04) iv1-iv63
    PubMedGoogle Scholar
  • 3 Howlader N, Noone AM, Krapcho M , et al. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2012/ . Accessed June 29, 2015
    PubMedGoogle Scholar
  • 4 Linn J, Brückmann H. Differential diagnosis of nontraumatic intracerebral hemorrhage. Klin Neuroradiol 2009; 19 (1) 45-61
    CrossrefPubMedGoogle Scholar
  • 5 van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6 (5) 421-430
    CrossrefPubMedGoogle Scholar
  • 6 Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004; 79 (12) 1489-1494
    CrossrefPubMedGoogle Scholar
  • 7 Kong X, Guan J, Yang Y, Li Y, Ma W, Wang R. A meta-analysis: do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures?. Clin Neurol Neurosurg 2015; 134: 98-103
    CrossrefPubMedGoogle Scholar
  • 8 Marcuse LV, Lancman G, Demopoulos A, Fields M. Nonconvulsive status epilepticus in patients with brain tumors. Seizure 2014; 23 (7) 542-547
    CrossrefPubMedGoogle Scholar
  • 9 Betjemann JP, Nguyen I, Santos-Sanchez C, Douglas VC, Josephson SA. Diagnostic yield of electroencephalography in a general inpatient population. Mayo Clin Proc 2013; 88 (4) 326-331
    CrossrefPubMedGoogle Scholar
  • 10 DeLorenzo RJ, Hauser WA, Towne AR , et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46 (4) 1029-1035
    CrossrefPubMedGoogle Scholar
  • 11 Brophy GM, Bell R, Claassen J , et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (1) 3-23
    CrossrefPubMedGoogle Scholar
  • 12 Cloughesy TF, Wen PY, Robins HI , et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006; 24 (22) 3651-3656
    CrossrefPubMedGoogle Scholar
  • 13 Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2 (7) 404-409
    CrossrefPubMedGoogle Scholar
  • 14 Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12 (2) 217-219
    CrossrefPubMedGoogle Scholar
  • 15 Chang EF, Potts MB, Keles GE , et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008; 108 (2) 227-235
    CrossrefPubMedGoogle Scholar
  • 16 Johnston PC, Hamrahian AH, Weil RJ, Kennedy L. Pituitary tumor apoplexy. J Clin Neurosci 2015; 22 (6) 939-944
    CrossrefPubMedGoogle Scholar
  • 17 Rajasekaran S, Vanderpump M, Baldeweg S , et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) 2011; 74 (1) 9-20
    CrossrefPubMedGoogle Scholar
  • 18 Bach F, Larsen BH, Rohde K , et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990; 107 (1–2) 37-43
    CrossrefPubMedGoogle Scholar
  • 19 Savage P, Sharkey R, Kua T , et al. Malignant spinal cord compression: NICE guidance, improvements and challenges. QJM 2014; 107 (4) 277-282
    CrossrefPubMedGoogle Scholar
  • 20 Barron KD, Hirano A, Araki S, Terry RD. Experiences with metastatic neoplasms involving the spinal cord. Neurology 1959; 9 (2) 91-106
    CrossrefPubMedGoogle Scholar
  • 21 Thawait SK, Kim J, Klufas RA , et al. Comparison of four prediction models to discriminate benign from malignant vertebral compression fractures according to MRI feature analysis. AJR Am J Roentgenol 2013; 200 (3) 493-502
    CrossrefPubMedGoogle Scholar
  • 22 Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ 1998; 317 (7150) 18-21
    CrossrefPubMedGoogle Scholar
  • 23 Patchell RA, Tibbs PA, Regine WF , et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366 (9486) 643-648
    CrossrefPubMedGoogle Scholar
  • 24 Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia 2009; 50 (Suppl. 12) 58-60
    PubMedGoogle Scholar
  • 25 Nassan G, Irani S, Bettcher B, Geschwind M, Gelfand J. Bradycardia leading to pacemaker placement: a characteristic prodromal syndrome of VGKCC/LGI1 antibody associated encephalitis. Neurol (Tokyo) 2014; 82 (10) (Suppl. 05) 195
    PubMedGoogle Scholar
  • 26 Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 2013; 14 (4) 528-538
    CrossrefPubMedGoogle Scholar
  • 27 Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9 (5) 453-461
    CrossrefPubMedGoogle Scholar
  • 28 Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006; 65 (2) 499-508
    CrossrefPubMedGoogle Scholar
  • 29 Wen PY, Macdonald DR, Reardon DA , et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11) 1963-1972
    CrossrefPubMedGoogle Scholar
  • 30 Levin VA, Bidaut L, Hou P , et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79 (5) 1487-1495
    CrossrefPubMedGoogle Scholar
  • 31 Baehring JM, Fulbright RK. Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 2008; 79 (5) 535-539
    CrossrefPubMedGoogle Scholar
  • 32 Carson KR, Newsome SD, Kim EJ , et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014; 120 (16) 2464-2471
    CrossrefPubMedGoogle Scholar
  • 33 Mateen FJ, Muralidharan R, Carone M , et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70 (2) 305-322
    CrossrefPubMedGoogle Scholar
  • 34 Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry 2010; 81 (7) 773-777
    CrossrefPubMedGoogle Scholar
  • 35 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
    CrossrefPubMedGoogle Scholar
  • 36 Dorth JA, Patel PR, Broadwater G, Brizel DM. Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy. Head Neck 2014; 36 (2) 215-219
    CrossrefPubMedGoogle Scholar